For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Lpath, Inc.

USPTO Granted Patents = 23

% Expired Patents = 100.0

EPO Patents = 10

Forward Citations = 50

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Roger A Sabbadini (22 out of 36 patents)

William A Garland (17 out of 38 patents)

Genevieve Hansen (13 out of 17 patents)

4. Steven Tarran Jones (7 out of 14 patents)

5. David Gareth Williams (7 out of 11 patents)

6. Glenn L Stoller (3 out of 3 patents)

7. Rosalia Matteo (2 out of 2 patents)

8. Scott R Pancoast (2 out of 2 patents)

9. Marina Safonov (2 out of 2 patents)

10. James Stephen Swaney (2 out of 2 patents)

11. Jonathan Michael Wojciak (2 out of 2 patents)

12. Gordon B Mills (1 out of 23 patents)

13. James Leigh Hsu (1 out of 1 patent)

14. Tom Huxford (1 out of 1 patent)

15. Amy L Cavalli (1 out of 1 patent)

23 patents: Sort by Forward Citations

1. 9274130 - Prevention and treatment of pain using antibodies to lysophosphatidic acid (2016-03-01),

2. 9274129 - Methods and reagents for detecting bioactive lipids (2016-03-01),

3. 9217749 - Immune-derived moieties reactive against lysophosphatidic acid (2015-12-22),

4. 9181331 - Pharmaceutical compositions for binding sphingosine-1-phosphate (2015-11-10),

5. 9163091 - Compositions and methods for binding lysophosphatidic acid (2015-10-20),

6. 9102718 - Anti-S1P antibody treatment of patients with ocular disease (2015-08-11),

7. 8871202 - Prevention and treatment of pain using antibodies to sphingosine-1-phosphate (2014-10-28),

8. 8796429 - Bioactive lipid derivatives, and methods of making and using same (2014-08-05),

9. 8614103 - Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions (2013-12-24),

10. 8604172 - Humanized antibody compositions and methods for binding lysophosphatidic acid (2013-12-10),

11. 8444970 - Compositions and methods for treating ocular diseases and conditions (2013-05-21),

12. 8401799 - Antibody design using anti-lipid antibody crystal structures (2013-03-19),

13. 8361465 - Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents (2013-01-29),

14. 8222373 - Humanized antibodies and compositions for binding sphingosine-1-phosphate (2012-07-17),

15. 8158124 - Compositions and methods for binding lysophosphatidic acid (2012-04-17),

Lpath, Inc. is a biotechnology company that develops bioactive lipid-targeted therapeutics. They utilize their proprietary ImmuneY2™ drug-discovery engine to discover and develop therapeutic antibodies that specifically target bioactive lipids. Lpath is dedicated to developing innovative treatments for ocular, cardiovascular, and inflammatory diseases to improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

23 Patents

#263 in San Diego, CA

#3,409 in California

#14,383 in US

#27,581 in the World

San Diego, CA, United States of America

Lpath, Inc.

Forward Citations = 50

15 inventors:

Roger A Sabbadini (22 out of 36 patents)

William A Garland (17 out of 38 patents)

Genevieve Hansen (13 out of 17 patents)

4. Steven Tarran Jones (7 out of 14 patents)

5. David Gareth Williams (7 out of 11 patents)

Please report any incorrect information to [email protected]

Loading…